GSK Discussing Paxil Pediatric Suicide Link With FDA; Label Change In U.K.
Executive Summary
GlaxoSmithKline is discussing with FDA whether Paxil data indicating an increased risk of "emotional lability" in pediatric patients on paroxetine should be communicated to physicians
You may also be interested in...
FDA Requests Antidepressant Labeling Add Suicidality Warning
FDA is requesting that labeling for 10 antidepressants include a warning recommending close monitoring of adult and pediatric patients for suicidal behavior
FDA Action On Antidepressants Questioned; Congress Widens Investigation
House and Senate Committees are requesting documentation from FDA officials on what and when they knew about a possible link between antidepressants and suicidal behavior
FDA Requests Antidepressant Labeling Add Suicidality Warning
FDA is requesting that labeling for 10 antidepressants include a warning recommending close monitoring of adult and pediatric patients for suicidal behavior